Kiniksa Pharmaceuticals International (KNSA) Projected to Announce Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is projected to post its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.30 per share and revenue of $226.4880 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. During the same period in the prior year, the company earned $0.11 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, analysts expect Kiniksa Pharmaceuticals International to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $62.84 on Friday. The company’s fifty day moving average is $56.87 and its 200 day moving average is $49.97. Kiniksa Pharmaceuticals International has a fifty-two week low of $26.27 and a fifty-two week high of $67.53. The stock has a market capitalization of $4.83 billion, a PE ratio of 69.82 and a beta of 0.07.

Insider Buying and Selling

In related news, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 628,427 shares of company stock worth $32,833,228 over the last three months. 51.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after purchasing an additional 90,194 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Kiniksa Pharmaceuticals International by 45.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after acquiring an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd grew its position in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after acquiring an additional 653,236 shares during the last quarter. Millennium Management LLC increased its stake in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Kiniksa Pharmaceuticals International by 51.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 829,417 shares of the company’s stock worth $34,213,000 after purchasing an additional 282,907 shares during the period. 53.95% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

KNSA has been the subject of several research reports. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the company an “outperform” rating in a research report on Monday, June 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Finally, Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $68.00.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.